Biotech Values

[DewDiligence]

TSBX IPOs 7.67M* shares @$12.00:

https://www.globenewswire.com/news-release/2023/07/21/2708700/0/en/Turnstone-Biologics-Corp-Announces-Pricing-of-Upsized-Initial-Public-Offering.html

Turnstone Biologics is a clinical-stage biotechnology company developing new medicines to treat and cure solid tumors by pioneering a differentiated approach to TIL therapy.

Turnstone’s innovative TIL therapy is based upon the identification, selection, and expansion of the most potent tumor-reactive T cells, known as Selected TILs, and is designed to overcome the limitations of first-generation bulk TILs that have demonstrated objective responses only in limited tumor types.

Turnstone’s most advanced program, TIDAL-01, is currently being evaluated in two Phase 1 studies in patients with melanoma, breast cancer, and colorectal cancer...

*Assuming exercise of underwriter’s option.